ES2049701T1 - Procedimiento de fabricacion de fibrinogeno con una pureza muy elevada. - Google Patents

Procedimiento de fabricacion de fibrinogeno con una pureza muy elevada.

Info

Publication number
ES2049701T1
ES2049701T1 ES93400247T ES93400247T ES2049701T1 ES 2049701 T1 ES2049701 T1 ES 2049701T1 ES 93400247 T ES93400247 T ES 93400247T ES 93400247 T ES93400247 T ES 93400247T ES 2049701 T1 ES2049701 T1 ES 2049701T1
Authority
ES
Spain
Prior art keywords
fibrinogen
solution
ionic strength
high purity
agarose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES93400247T
Other languages
English (en)
Other versions
ES2049701T3 (es
Inventor
Bernard Dazey
Mohamed Hamsany
Sylvia Enfedaque-Morer
Gerard Vezon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AQUITAINE DEV TRANSF SANGUINE
Original Assignee
AQUITAINE DEV TRANSF SANGUINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AQUITAINE DEV TRANSF SANGUINE filed Critical AQUITAINE DEV TRANSF SANGUINE
Publication of ES2049701T1 publication Critical patent/ES2049701T1/es
Application granted granted Critical
Publication of ES2049701T3 publication Critical patent/ES2049701T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCESO DE FABRICACION DE FIBRINOGENO DE ALTA PUREZA. ESTE PROCESO SE CARACTERIZA EN QUE COMPRENDE, A PARTIR DE CRIOPRECIPITADO DE PLASMA SANGUINEO DE ORIGEN ANIMAL O HUMANO, PUESTO EN SOLUCION ACUOSA, EL TRATAMIENTO DE ESTA SOLUCION PARA LLEVARLA A UNA FUERZA IONICA IGUAL A LA DE UNA SOLUCION TAMPON QUE TIENE LA SIGUIENTE COMPOSICION: NACL 120MM TRIS 20 MM PH 8,8 SE HACE PASAR ESTA SOLUCION DE FUERZA IONICA AJUSTA SOBRE UNA COLUMNA INTERCAMBIADORA DE ANION QUE COMPRENDE UN GEL DE INTERCAMBIO DE ANION, POR EJEMPLO EN FORMA DE BOLAS, A BASE DE AGAROSA RETICULADO QUE COMPRENDE GRUPOS AMINO CUATERNARIO PARTICULARMENTE EN EL EXTREMO DE UN PEQUEÑO BRAZO SEPARADO, POR EJEMPLO DE TIPO ALQUILENO EN C1-C6 CONECTADO A LAS BOLAS DE AGAROSA, EN PARTICULAR A APROXIMADAMENTE 6% DE AGAROSA Y SE PROCEDE A UNA ELUCION CON UNA PRIMERA SOLUCION DE ELUCION DE IGUAL FUERZA IONICA, PERMITIENDO ESTAS CONDICIONES ABSORBER AL MENOS SELECTIVAMENTE EL FIBRINOGENO SOBRE DICHA COLUMNA, QUEESTA DESORBIDO POR UNA SOLUCION DE ELUCION DE FUERZA IONICA MAS ELEVADA A 200 MM NACL. SE OBTIENE UN FIBRINOGENO DE ALTA PUREZA.
ES93400247T 1992-02-04 1993-02-02 Procedimiento de fabricacion de fibrinogeno de pureza muy elevada. Expired - Lifetime ES2049701T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201238A FR2686883B1 (fr) 1992-02-04 1992-02-04 Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.

Publications (2)

Publication Number Publication Date
ES2049701T1 true ES2049701T1 (es) 1994-05-01
ES2049701T3 ES2049701T3 (es) 1997-01-16

Family

ID=9426316

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93400247T Expired - Lifetime ES2049701T3 (es) 1992-02-04 1993-02-02 Procedimiento de fabricacion de fibrinogeno de pureza muy elevada.

Country Status (7)

Country Link
EP (1) EP0555135B1 (es)
AT (1) ATE141284T1 (es)
DE (2) DE555135T1 (es)
DK (1) DK0555135T3 (es)
ES (1) ES2049701T3 (es)
FR (1) FR2686883B1 (es)
GR (2) GR930300095T1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2887329B2 (ja) * 1991-09-05 1999-04-26 バクスター インターナショナル インク 局所用フィブリノーゲン複合体
DE69512416T3 (de) * 1994-07-14 2011-12-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
WO2009155626A2 (de) 2008-06-23 2009-12-30 Bio-Products & Bio-Engineering Ag Lagerstabiles, funktionell intaktes fibrinogen
CN103328503B (zh) * 2010-09-20 2016-08-24 欧克塔医药公司 纤维蛋白原生产方法
US10112972B2 (en) 2012-03-13 2018-10-30 Octapharma Ag Process for production of fibrinogen and fibrinogen produced thereby
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo

Also Published As

Publication number Publication date
FR2686883A1 (fr) 1993-08-06
GR930300095T1 (en) 1993-09-30
DE69303941D1 (de) 1996-09-19
DE69303941T2 (de) 1997-03-27
ATE141284T1 (de) 1996-08-15
EP0555135A1 (fr) 1993-08-11
DE555135T1 (de) 1994-03-31
ES2049701T3 (es) 1997-01-16
GR3021419T3 (en) 1997-01-31
DK0555135T3 (da) 1996-11-25
EP0555135B1 (fr) 1996-08-14
FR2686883B1 (fr) 1994-05-13

Similar Documents

Publication Publication Date Title
USRE44558E1 (en) Chromatographic method for high yield purification and viral inactivation of antibodies
ATE179425T1 (de) Verfahren zur abreicherung oder entfernung von endotoxinen
IE44507B1 (en) Cationic material capable of reversibly fixing biological macromolecules
EP0121976A3 (en) Partially purified osteogenic factor and process for preparing same from demineralized bone or an osteosarcoma
NZ509135A (en) A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
ES2049701T1 (es) Procedimiento de fabricacion de fibrinogeno con una pureza muy elevada.
RU2010139827A (ru) Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах
CA2058676C (en) Process for isolating human albumin from supernatant iv, in particular iv-4, or from cohn's fraction v or from an analogous supernatant or fraction
US6955917B2 (en) Chromatographic method for high yield purification and viral inactivation of antibodies
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
CA1133898A (en) Purification of interferon
RS51512B (sr) Postupak za prečišćavanje interferonskih proteina pomoću katjonske izmenjivačke hromatografije
US4677197A (en) Purification method for tumor necrosis factor
ATE222925T1 (de) Verbessertes verfahren zur herstellung von faktor viii
US4985144A (en) Affinity chromatography material for antigens of the bacteria of the Bordetella genus
KR860002570A (ko) 백일해 성분 백신 및 백일해항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법
KR960705921A (ko) 사람 활성화 단백질 C제제 및 이의 제조 방법(Human activated protein C preparation and process for producing the same)
WO1996016084A3 (en) A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
ATE528393T1 (de) Verfahren zur reinigung von protein und glucosedehydrogenase
EP0868507B1 (en) Process for the purification of urease from helicobacter pylori
CA2154231A1 (fr) Procede de preparation d'un concentre d'inhibiteur de la c1-esterase (c1-inh), et concentre obtenu, a usage therapeutique
KR920700220A (ko) 활성 단백질c의 제조방법과 이러한 방법으로 제조된 활성 단백질c
JPH038196B2 (es)
JPH03244390A (ja) 大腸菌由来物質の除去方法
JPH04126092A (ja) 大腸菌由来蛋白の除去方法

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 555135

Country of ref document: ES